Comparative Pharmacology
Head-to-head clinical analysis: GILDESS 1 5 30 versus NORINYL 1 50 28 DAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GILDESS 1 5 30 versus NORINYL 1 50 28 DAY.
GILDESS 1.5/30 vs NORINYL 1+50 28-DAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of estrogen (ethinyl estradiol) and progestin (desogestrel) that inhibits gonadotropin release, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial morphology.
Norethindrone and ethinyl estradiol combination works by suppressing gonadotropin-releasing hormone (GnRH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby inhibiting ovulation. Norethindrone also alters cervical mucus viscosity and endometrial lining, impeding sperm penetration and implantation.
One tablet orally once daily at the same time each day.
One tablet orally once daily for 28 days, with 7 inactive tablets during the last 7 days. Each active tablet contains norethindrone 1 mg and ethinyl estradiol 50 mcg.
None Documented
None Documented
Ethinylestradiol: terminal half-life 13-17 hours (mean 15 h). Desogestrel active metabolite 3-keto-desogestrel: terminal half-life 23-28 hours (mean 25 h). Clinical: steady-state achieved by cycle day 7-10; missed pill instructions based on half-life.
Norethindrone: ~8-11 hours; Mestranol: 24 hours (prodrug, ethinyl estradiol half-life ~13-27 hours).
Renal: ~55-60% as ethinylestradiol glucuronide and sulfate conjugates; ~40% as desogestrel metabolites (largely as 3-keto-desogestrel glucuronide). Fecal: ~30-35% of desogestrel metabolites; <5% for ethinylestradiol. Biliary: minor for both.
Renal: ~40% as metabolites; Biliary/Fecal: ~60% as metabolites.
Category C
Category C
Oral Contraceptive
Oral Contraceptive